Official Title
Managed Access Program (MAP) to Provide Access to Trametinib and Dabrafenib Combination Therapy in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
Brief Summary

The purpose of this Treatment Plan is to allow access to trametinib and dabrafenib for eligible high-risk BRAF mutation-positive patients in the adjuvant treatment of melanoma after surgical resection. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Detailed Description

The requesting Treating Physician submitted a request for access to drug (often referred to

as Compassionate Use) to Novartis which was reviewed and approved by the medical team

experienced with the drug and indication.

This program will provide access to patients until:

- All participating countries have received marketing authorization and product is

commercially available and accessible to all participating patient(s) or

- Alternative treatment options are available and/or

- In case of changes in the safety profile or a lack of overall efficacy of the product.

Treatment IND/Protocol

Drug: Dabrafenib and Trametinib
The starting dose of the combination treatment will be administered as follows:
Dabrafenib, 150 mg, twice daily (BID);
Trametinib, 2.0 mg, once daily (QD)

Drug: Dabrafenib
If administration of dabrafenib is interrupted or permanently discontinued, administration of trametinib may continue.

Drug: Trametinib
If administration of trametinib is interrupted or permanently discontinued, administration of dabrafenib may be continued.

Eligibility Criteria

Inclusion Criteria: 1. Has or is willing to give consent to the Treating Physician in accordance with the local regulatory requirements. 2. Has the following diagnosis: Completely resected (R0) histologically confirmed high-risk (stage III) cutaneous melanoma with confirmed BRAF V600E/K activating mutation. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible. Patients with an unknown primary melanoma are not eligible. 3. All clinical trials that the patient might qualify for have been ruled out. 4. Is receiving care at a clinical site with a Treating Physician who has experience with administering investigational agents for patients with this condition, or the patient is willing and/or able to travel to a site and receive treatment under the guidance of physician with this experience. 5. Is able to retain oral medication and swallow tablets/capsules (appropriate exceptions allowed for patients who are unable to swallow tablets/capsules - this is subject to availability of alternative (liquid) oral formulations). 6. Is not eligible for participation in any of the IMP's ongoing clinical trials or has recently completed a clinical trial that has been terminated and, after considering other options (e.g., trial extensions, amendments, etc.), the clinical team has determined that treatment is necessary and there are no other feasible alternatives for the patient. 7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3 (or equivalent) and is in stable clinical condition. NOTE: patient in rapidly deteriorating clinical condition prior to start of therapy should not be considered for this program. 8. Does not require treatment with prohibited concomitant medications (please refer to the IB or approved label/SmPC). 9. Women of childbearing potential must have had a negative serum β-human chorionic gonadotropin (HCG) pregnancy test within 7 days prior to starting dabrafenib and trametinib treatment. Subjects with a positive pregnancy test result must be excluded from the program. Subjects with a negative pregnancy test result must agree to use an effective contraception method as described below throughout the treatment period and for a total of 4 months following the last dose of treatment.

Contraceptive Methods for Females of Childbearing Potential: - An intrauterine device with a documented failure rate of less than 1% per year - Vasectomized partner who is sterile prior to the female patient's entry into the Compassionate Use program, and this male is the sole sexual partner for that female. - Complete abstinence from sexual intercourse for 14 days prior to first dose of treatment, through the dosing period, and for at least 4 months after the last dose of treatment. Abstinence is only acceptable when in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception. - Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with vaginal spermicidal agent (foam/gel/cream/suppository).

Note: Hormonal-based methods (e.g., oral contraceptives) are not permitted as contraception
due to potential drug-drug interactions with dabrafenib.

Females Not of Childbearing Potential Non-childbearing potential (i.e., physiologically
incapable of becoming pregnant) is defined as any female who has had a documented
hysterectomy, bilateral oophorectomy (ovariectomy), bilateral tubal ligation or tubal
occlusion, or is post-menopausal.

A practical definition accepts menopause after 1 year without menses with an appropriate
clinical profile; e.g., age appropriate, >45 years in the absence of hormone replacement
therapy (HRT). In questionable cases, the patient must have a follicle stimulating hormone
(FSH) value >40 mIU/mL and an estradiol value

Eligibility Gender
Eligibility Age
Maximum: 100 Years

Novartis Pharmaceuticals

Novartis Pharmaceuticals

Novartis Pharmaceuticals
NCT Number
Malignant skin cancer
Skin cancer
Stage III melanoma
Surgical resection
Compassionate Use
MeSH Terms
Intervention Name
Dabrafenib and Trametinib